GONG, B.S., D. LI, R. KUSKO, N. NOVORADOVSKAYA, Y.F. ZHANG, S.Z. WANG, C. PABON-PENA, Z.H. ZHANG, K. LAI, W.S. CAI, J.S. LOCOCO, E. LADER, T.A. RICHMOND, V.K. MITTAL, L.C. LIU, D.J. JOHANN, J.C. WILLEY, P.R. BUSHEL, Y. YU, C. XU, G.C. CHEN, D. BURGESS, S. CAWLEY, K. GIORDA, N. HASELEY, F.J. QIU, K. WILKINS, H. ARIB, C. ATTWOOLL, K. BABSON, L.L. BAO, W.J. BAO, A.B. LUCAS, H. BEST, A. BHANDARI, H. BISGIN, J. BLACKBURN, T.M. BLOMQUIST, L. BOARDMAN, B. BURGHER, D.J. BUTLER, C.J. CHANG, A. CHAUBEY, T. CHEN, M. CHIERICI, C.R. CHIN, D. CLOSE, J. CONROY, J.C. COLEMAN, D.J. CRAIG, E. CRAWFORD, A. DEL POZO, I.W. DEVESON, D. DUNCAN, A.K. ETEROVIC, X.H. FAN, J. FOOX, C. FURLANELLO, A. GHOSAL, S. GLENN, M.J. GUAN, C. HAAG, X.Y. HANG, S. HAPPE, B. HENNIGAN, J. HIPP, H.X. HONG, K. HORVATH, J.H. HU, L.Y. HUNG, M. JAROSZ, J. KERKHOF, B. KIPP, D.P. KREIL, P. LAPUNZINA, P. LI, Q.Z. LI, W.H. LI, Z.G. LI, Y. LIANG, S.Q. LIU, Z.C. LIU, C. MA, N. MARELLA, R. MARTIN-ARENAS, D.B. MEGHERBI, Q.C. MENG, P.A. MIECZKOWSKI, T. MORRISON, D. MUZNY, B.T. NING, B.L. PARSONS, C.P. PAWELETZ, M. PIROOZNIA, W.B. QU, A. RAYMOND, P. RINDLER, R. RINGLER, B. SADIKOVIC, A. SCHERER, E. SCHULZE, R. SEBRA, R. SHAKNOVICH, Q. SHI, T.L. SHI, J.C. SILLA-CASTRO, M. SMITH, M.S. LOPEZ, P. SONG, D. STETSON, M. STRAHL, A. STUART, J. SUPPLEE, P. SZANKASI, H.W. TAN, L.Y. TANG, Y.H. TAO, S. THAKKAR, D. THIERRY-MIEG, J. THIERRY-MIEG, V.J. THODIMA, D. THOMAS, Boris TICHÝ, Nikola TOM, E.V. GARCIA, S. VERMA, K. WALKER, C. WANG, J.W. WANG, Y.X. WANG, Z.N. WEN, V. WIRTA, L.H. WU, C.L. XIAO, W.Z. XIAO, S.B. XU, M. YANG, J.M. YING, S.H. YIP, G.L. ZHANG, S. ZHANG, M.R. ZHAO, Y.T. ZHENG, X.Y. ZHOU, C.E. MASON, T. MERCER, W.D. TONG, L.M. SHI, W. JONES and J.S. XU. Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions. GENOME BIOLOGY. LONDON: BIOMED CENTRAL LTD, 2021, vol. 22, No 1, p. 109-131. ISSN 1474-760X. Available from: https://dx.doi.org/10.1186/s13059-021-02315-0.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions
Authors GONG, B.S., D. LI, R. KUSKO, N. NOVORADOVSKAYA, Y.F. ZHANG, S.Z. WANG, C. PABON-PENA, Z.H. ZHANG, K. LAI, W.S. CAI, J.S. LOCOCO, E. LADER, T.A. RICHMOND, V.K. MITTAL, L.C. LIU, D.J. JOHANN, J.C. WILLEY, P.R. BUSHEL, Y. YU, C. XU, G.C. CHEN, D. BURGESS, S. CAWLEY, K. GIORDA, N. HASELEY, F.J. QIU, K. WILKINS, H. ARIB, C. ATTWOOLL, K. BABSON, L.L. BAO, W.J. BAO, A.B. LUCAS, H. BEST, A. BHANDARI, H. BISGIN, J. BLACKBURN, T.M. BLOMQUIST, L. BOARDMAN, B. BURGHER, D.J. BUTLER, C.J. CHANG, A. CHAUBEY, T. CHEN, M. CHIERICI, C.R. CHIN, D. CLOSE, J. CONROY, J.C. COLEMAN, D.J. CRAIG, E. CRAWFORD, A. DEL POZO, I.W. DEVESON, D. DUNCAN, A.K. ETEROVIC, X.H. FAN, J. FOOX, C. FURLANELLO, A. GHOSAL, S. GLENN, M.J. GUAN, C. HAAG, X.Y. HANG, S. HAPPE, B. HENNIGAN, J. HIPP, H.X. HONG, K. HORVATH, J.H. HU, L.Y. HUNG, M. JAROSZ, J. KERKHOF, B. KIPP, D.P. KREIL, P. LAPUNZINA, P. LI, Q.Z. LI, W.H. LI, Z.G. LI, Y. LIANG, S.Q. LIU, Z.C. LIU, C. MA, N. MARELLA, R. MARTIN-ARENAS, D.B. MEGHERBI, Q.C. MENG, P.A. MIECZKOWSKI, T. MORRISON, D. MUZNY, B.T. NING, B.L. PARSONS, C.P. PAWELETZ, M. PIROOZNIA, W.B. QU, A. RAYMOND, P. RINDLER, R. RINGLER, B. SADIKOVIC, A. SCHERER, E. SCHULZE, R. SEBRA, R. SHAKNOVICH, Q. SHI, T.L. SHI, J.C. SILLA-CASTRO, M. SMITH, M.S. LOPEZ, P. SONG, D. STETSON, M. STRAHL, A. STUART, J. SUPPLEE, P. SZANKASI, H.W. TAN, L.Y. TANG, Y.H. TAO, S. THAKKAR, D. THIERRY-MIEG, J. THIERRY-MIEG, V.J. THODIMA, D. THOMAS, Boris TICHÝ (203 Czech Republic, belonging to the institution), Nikola TOM (203 Czech Republic, belonging to the institution), E.V. GARCIA, S. VERMA, K. WALKER, C. WANG, J.W. WANG, Y.X. WANG, Z.N. WEN, V. WIRTA, L.H. WU, C.L. XIAO, W.Z. XIAO, S.B. XU, M. YANG, J.M. YING, S.H. YIP, G.L. ZHANG, S. ZHANG, M.R. ZHAO, Y.T. ZHENG, X.Y. ZHOU, C.E. MASON, T. MERCER, W.D. TONG, L.M. SHI, W. JONES and J.S. XU.
Edition GENOME BIOLOGY, LONDON, BIOMED CENTRAL LTD, 2021, 1474-760X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 17.906
RIV identification code RIV/00216224:14740/21:00120110
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1186/s13059-021-02315-0
UT WoS 000641654300001
Keywords in English Oncopanel sequencing; Target enrichment; Molecular diagnostics; Reproducibility; Analytical performance; Precision medicine
Tags CF GEN, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 18/5/2022 13:17.
Abstract
BackgroundTargeted sequencing using oncopanels requires comprehensive assessments of accuracy and detection sensitivity to ensure analytical validity. By employing reference materials characterized by the U.S. Food and Drug Administration-led SEquence Quality Control project phase2 (SEQC2) effort, we perform a cross-platform multi-lab evaluation of eight Pan-Cancer panels to assess best practices for oncopanel sequencing.ResultsAll panels demonstrate high sensitivity across targeted high-confidence coding regions and variant types for the variants previously verified to have variant allele frequency (VAF) in the 5-20% range. Sensitivity is reduced by utilizing VAF thresholds due to inherent variability in VAF measurements. Enforcing a VAF threshold for reporting has a positive impact on reducing false positive calls. Importantly, the false positive rate is found to be significantly higher outside the high-confidence coding regions, resulting in lower reproducibility. Thus, region restriction and VAF thresholds lead to low relative technical variability in estimating promising biomarkers and tumor mutational burden.ConclusionThis comprehensive study provides actionable guidelines for oncopanel sequencing and clear evidence that supports a simplified approach to assess the analytical performance of oncopanels. It will facilitate the rapid implementation, validation, and quality control of oncopanels in clinical use.
Links
LM2015064, research and development projectName: Český národní uzel Evropské infrastruktury pro translační medicínu (Acronym: EATRIS-ERIC-CZ)
Investor: Ministry of Education, Youth and Sports of the CR
LM2018133, research and development projectName: Český národní uzel Evropské infrastruktury pro translační medicínu (Acronym: EATRIS-ERIC-CZ)
Investor: Ministry of Education, Youth and Sports of the CR
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
NV19-03-00091, research and development projectName: Komplexní prognostický a prediktivní panel pro pacienty s chronickou lymfocytární leukémií: nástroj sekvenování nové generace vhodný pro klinickou praxi i studium genetického pozadí průběhu choroby
Investor: Ministry of Health of the CR
PrintDisplayed: 25/4/2024 02:09